Apogee has successfully licensed exclusive rights to ABC294640 to RedHill Biopharma. Apogee looks forward to working closely with RedHill for late stage clinical development in many cancer and inflammatory indications. http://globenewswire.com/news-release/2015/03/31/720531/10126995/en/RedHill-Biopharma-Acquires-Phase-II-First-in-Class-Oral-Small-Molecule-SK2-Inhibitor-From-Apogee-Biotech.html
Apogee completed enrollment on the initial safety trial for ABC294640 in advanced solid tumor cancer patients. Results showed that the ABC294640 safety profile correlated well to that observed in preclinical toxicology studies and that ABC294640 had an excellent pharmacokinetic profile that modulated the pharmacodynamic marker of circulating spingosine-1-phosphate as expected. The results from this trial […]
A Non-Formula Commonwealth Universal Research Enhancement (CURE) Program grant in the amount of $832,608 was awarded to Apogee to support preclinical research on Apogee’s phase I clinical drug, ABC294640. The funds will support research to determine the optimum treatment protocols for the combination of ABC294640 with current standard of care drugs for pancreatic cancer. ABC294640 […]
The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) recently released information about the award.
Apogee is pleased to announce approval from the Food and Drug Administration for the Investigational New Drug Application for ABC294640 for advanced solid tumors and advanced pancreatic cancer . Apogee anticipates the start of the clinical trial at the beginning of 2011.